Literature DB >> 7720765

Induction of cytochrome P4501A by smoking or omeprazole in comparison with UDP-glucuronosyltransferase in biopsies of human duodenal mucosa.

J Buchthal1, K E Grund, A Buchmann, D Schrenk, P Beaune, K W Bock.   

Abstract

Drug-metabolizing enzymes were investigated in duodenal biopsy specimens. Cytochrome P4501A (CYP1A) activity was determined by measuring 7-ethoxyresorufin O-deethylase (EROD) activity in biopsies from 20 smokers (3-30 cigarettes per day), 21 nonsmokers, and 10 nonsmokers receiving omeprazole treatment (20-60 mg/day for at least 1 week). Omeprazole is known to act as a polycyclic aromatic hydrocarbon (PAH)-type inducer in humans. EROD activity was found to be significantly induced in smokers and omeprazole-treated patients, with medians of 2.1 and 1.1 pmol.min-1.mg protein-1, respectively, compared with 0.5 pmol.min-1.mg protein-1 in nonsmokers. Immunoblot analysis substantiated that EROD activity was correlated with CYP1A protein. In contrast, UDP-glucuronosyltransferase (UGT) activity towards 4-methylumbelliferone (an overlapping substrate of several constitutive and inducible UGTs) was not significantly affected. The results demonstrate CYP1A induction by omeprazole and by constituents of cigarette smoke in the human duodenum and support the utility of duodenal biopsies to monitor CYP1A induction by PAH-type inducers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7720765     DOI: 10.1007/bf00196857

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  44 in total

1.  The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.

Authors:  K W Bock; D Schrenk; A Forster; E U Griese; K Mörike; D Brockmeier; M Eichelbaum
Journal:  Pharmacogenetics       Date:  1994-08

Review 2.  Genetic and molecular aspects of 2,3,7,8-tetrachlorodibenzo-p-dioxin action.

Authors:  J P Whitlock
Journal:  Annu Rev Pharmacol Toxicol       Date:  1990       Impact factor: 13.820

3.  Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450.

Authors:  D Diaz; I Fabre; M Daujat; B Saint Aubert; P Bories; H Michel; P Maurel
Journal:  Gastroenterology       Date:  1990-09       Impact factor: 22.682

4.  Effects of semisynthetic diets on xenobiotic metabolizing enzyme activity and morphology of small intestinal mucosa in humans.

Authors:  H P Hoensch; H J Steinhardt; G Weiss; D Haug; A Maier; H Malchow
Journal:  Gastroenterology       Date:  1984-06       Impact factor: 22.682

5.  Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes.

Authors:  R E Kouri; C E McKinney; D J Slomiany; D R Snodgrass; N P Wray; T L McLemore
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

6.  Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking.

Authors:  K W Bock; J Wiltfang; R Blume; D Ullrich; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract.

Authors:  W M McDonnell; J M Scheiman; P G Traber
Journal:  Gastroenterology       Date:  1992-11       Impact factor: 22.682

8.  Mono- and diglucuronide formation from chrysene and benzo(a)pyrene phenols by 3-methylcholanthrene-inducible phenol UDP-glucuronosyltransferase (UGT1A1).

Authors:  K W Bock; H Gschaidmeier; A Seidel; S Baird; B Burchell
Journal:  Mol Pharmacol       Date:  1992-10       Impact factor: 4.436

Review 9.  Aryl hydrocarbon or dioxin receptor: biologic and toxic responses.

Authors:  K W Bock
Journal:  Rev Physiol Biochem Pharmacol       Date:  1994       Impact factor: 5.545

10.  Interindividual difference in expression of human Ah receptor and related P450 genes.

Authors:  S Hayashi; J Watanabe; K Nakachi; H Eguchi; O Gotoh; K Kawajiri
Journal:  Carcinogenesis       Date:  1994-05       Impact factor: 4.944

View more
  7 in total

1.  Loss of orally administered drugs in GI tract.

Authors:  Yogeshkumar Nanasaheb Gavhane; Adhikrao Vyankatrao Yadav
Journal:  Saudi Pharm J       Date:  2012-04-20       Impact factor: 4.330

Review 2.  Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.

Authors:  Gail D Anderson; Lingtak-Neander Chan
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

3.  Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue, in cancer patients with solid tumors.

Authors:  Fei Tang; Eleftheria Tsakalozou; Susanne M Arnold; Chee M Ng; Markos Leggas
Journal:  Invest New Drugs       Date:  2019-02-28       Impact factor: 3.850

Review 4.  Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.

Authors:  U A Meyer
Journal:  Yale J Biol Med       Date:  1996 May-Jun

5.  Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.

Authors:  Maxim Kuzin; Georgios Schoretsanitis; Ekkehard Haen; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Michael Paulzen
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

Review 6.  Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes.

Authors:  Florian Klomp; Christoph Wenzel; Marek Drozdzik; Stefan Oswald
Journal:  Pharmaceutics       Date:  2020-12-11       Impact factor: 6.321

7.  Gene and protein expression and cellular localisation of cytochrome P450 enzymes of the 1A, 2A, 2C, 2D and 2E subfamilies in equine intestine and liver.

Authors:  Eva Tydén; Hans Tjälve; Pia Larsson
Journal:  Acta Vet Scand       Date:  2014-10-08       Impact factor: 1.695

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.